期刊
COLLOIDS AND SURFACES B-BIOINTERFACES
卷 116, 期 -, 页码 652-657出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.colsurfb.2013.10.038
关键词
Mesoporous silica nanoparticles; Ultrasound; Contrast agent; Breast cancer; Drug delivery; Herceptin
资金
- University of Colorado start-up grant
- Cancer Center Support Grant [P30CA046934]
Ultrasound (US) is used widely in the context of breast cancer. While it is advantageous for a number of reasons, it has low specificity and requires the use of a contrast agent. Its use as a standalone diagnostic and real-time imaging modality could be achieved by development of a tumor-targeted ultrasound contrast agent (UCA); functionalizing the UCA with a tumor-targeting agent would also allow the targeted administration of anti-cancer drugs at the tumor site. In this article, clinical US techniques are used to show that mesoporous silica nanoparticles (MSNs), functionalized with the monoclonal antibody Herceptin (R), can be used as an effective UCA by increasing US image contrast. Furthermore, in vitro assays show the successful localization and binding of the MSN-Herceptin conjugate to HER2+ cancer cells, resulting in tumor-specific cytotoxicity. These results demonstrate the potential of MSNs as a stable, biocompatible, and effective therapeutic and diagnostic (theranostic) agent for US-based breast cancer imaging, diagnosis, and treatment. (C) 2013 Elsevier B.V. All rights reserved,
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据